Daily treatment for erectile dysfunction using a PDE5 inhibitor

An article of manufacture for human pharmaceutical use comprising:

• (a) an oral dosage form comprising a PDE5 inhibitor having an IC50 less than 10 nM, and a sufficient bioavailability to be effective in about 1 to about 10 mg unit oral dosages;
• (b) a package insert providing that the PDE5 inhibitor is useful to treat sexual dysfunction in a patient in need thereof by utilizing a chronic dosing regimen, wherein the chronic dosing regimen improves vascular conditioning;
• and
• (c) a container.

An article of manufacture for human pharmaceutical use comprising:

• (a) an oral dosage form comprising a PDE5 inhibitor having an IC50 less than 10 nM, and a sufficient bioavailability to be effective in about 1 to about 10 mg unit oral dosages;
• (b) a package insert providing that the PDE5 inhibitor is useful to treat sexual dysfunction in a patient in need thereof by utilizing a chronic dosing regimen, wherein the chronic dosing regimen improves vascular conditioning compared to an acute or on-demand dosing of sildenafil;
• and
• (c) a container.

An article of manufacture for human pharmaceutical use comprising:

• (a) an oral dosage form comprising a PDE5 inhibitor having an IC50 less than 10 nM, and a sufficient bioavailability to be effective in about 1 to about 10 mg unit oral dosages;
• (b) a package insert providing that the PDE5 inhibitor is useful to treat sexual dysfunction in a patient in need thereof by utilizng a chronic dosing regimen, wherein the chronic dosing regimen improves vascular conditioning compared to an acute or on-demand dosing of vardenafil;
• and
• (c) a container.